All of the mAbs neutralize the infection in different combinations of HCMV strains and target cells , with a potency ~20 fold higher than that of the HCMV hyperimmune globulins ,
Recombinant human monoclonal IgG1 suitable as a prophylactic or therapeutic tool in clinical applications has been generated .
All of the mAbs neutralize the infection in different combinations of HCMV strains and target cells , with a potency ~20 fold higher than that of the HCMV hyperimmune globulins , currently used in transplant recipients .
Recombinant human monoclonal IgG1 suitable as a prophylactic or therapeutic tool in clinical applications has been generated .